Xenetic Biosciences, Inc.

Home
United States
Framingham, MA
Xenetic Biosciences, Inc.

XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Ltd.

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

10/16/2025

Our oncology platform is built with one goal: to make cancer treatments more effective. With the potential to target multiple indications, we’re working to change outcomes and bring new hope to patients.

Find out more: https://bit.ly/3PkEMfi

10/10/2025

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

https://bit.ly/4ohNkDm

10/01/2025

Subscribe to our email alerts to stay informed about our latest news and events: https://bit.ly/3zXgBLd

09/25/2025

: Dr. Reid Bissonnette, Translational Research and Development

A key part of , he brings 25+ years of experience in small molecule and biotherapeutics R&D across oncology, immuno-oncology and inflammation, advancing therapies from discovery to clinic through translational science, IND-enabling studies, biomarkers and clinical trial design.

Learn more: https://bit.ly/4dd8mx0

09/16/2025

Curious about our DNase technologies? Discover how we’re advancing treatments here: https://bit.ly/3Aj9iSL

09/10/2025

Our lead program is advancing toward new treatments for — the third deadliest cancer in the U.S., with 62,000 diagnoses and 50,000 deaths each year.

08/27/2025

Our data suggests NETs degradation by DNase I plays a crucial role in maintaining CAR T-cell function and preventing premature CAR T-cell exhaustion.

Learn more: https://bit.ly/4mJ0Qzy

08/22/2025

At Xenetic, we remain committed to advancing our systemic recombinant human DNase I technology into the clinical stage.

08/18/2025

Our DNase I Platform employs an enzyme designed to eliminate NETs. Discover more here: https://bit.ly/47DW931

08/13/2025

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

https://bit.ly/3JcVzkQ

08/12/2025

Explore everything you need to know about in our latest investor deck.

Take a look: https://bit.ly/3LgHpg2

Address

40 Speen Street
Framingham, MA
01701

Telephone

+17817787720

Website

http://www.xeneticbio.com/

Alerts

Be the first to know and let us send you an email when Xenetic Biosciences, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Xenetic Biosciences, Inc.:

Want your practice to be the top-listed Clinic in Framingham?

Our Story

Xenetic Biosciences (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.